TABLE 3.
Predictive biomarkers for PD-1/PD-L1 blockade in combination with other cancer treatment regimens.
| Biomarker | Additional therapy | Association with favourable clinical outcome | Tissue type for biomarker assessment | Assay type for biomarker assessment | Clinical trials |
|---|---|---|---|---|---|
| PD-L1 expression | Chemotherapy | Positive | Tumor | QIF | NCT02489448 |
| Chemotherapy | Positive | Tumor | IHC | NCT02622074 | |
| Chemotherapy | Positive | Tumor | IHC | NCT02685059 | |
| Anti-HER2 | Positive | Tumor | IHC | NCT02605915 | |
| Anti-HER2 | Positive | Tumor | IHC | NCT02649686 | |
| Anti-HER2 | Positive | Tumor | IHC | NCT02924883 | |
| PARPi | Positive | Tumor | IHC | NCT02734004 | |
| TIL status | Chemotherapy | Positive | Tumor | HE | NCT02622074 |
| Chemotherapy | Positive | Tumor | HE | NCT02685059 | |
| Anti-HER2 | positive | Tumor | HE | NCT02924883 | |
| Anti-HER2 | Positive | Tumor | HE | NCT02129556 | |
| TKI | Positive | Tumor | HE | NCT03394287 | |
| PARPi | Positive | Tumor | — | NCT02734004 | |
| Immune signatures | Irradiation, chemotherapy | Positive | Tumor | NanoString | NCT02499367 |
| Anti-HER2 | Positive | Tumor | RNA-seq | NCT02924883 | |
| PARPi + chemotherapy | Positive/Negative | Tumor | Microarray | NCT01042379 | |
| Specific T cell subtypes-Tregs | Anti-angiogenesis | Negative | Blood | Gallios cytometer | NCT02802098 |
| TMB | Androgen receptor agonist | Positive | Tumor | TEMPUS xT genome alteration panel | NCT02971761 |
Abbreviations: TIL, tumor infiltrating lymphocyte; QIF, quantitative immunofluorescence; IHC, immunohistochemistry; HE, hematoxylin and eosin stain; TMB, tumor mutation burden.